Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHF 1535 Next DPI vs HFA pMDI in Moderate to Severe Asthma
NCT00862394Phase 3Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Feb 2009
- Primary completion
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of beclomethasone dipropionate and formoterol in asthma (4 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Forced Expiratory Volume in 1 second at 12 weeks. Started Feb 2009; status: completed.
02
Drugs
beclomethasone dipropionateformoterol
03
Conditions
asthma
Beyond the preview
Go deeper on NCT00862394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00862394.